Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.addr.2015.02.002 http://scihub22266oqcxt.onion/10.1016/j.addr.2015.02.002 C4504788!4504788!25689735     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Adv+Drug+Deliv+Rev 2015 ; 87 (ä): 81-9 Nephropedia Template TP {{tp|p=25689735|t=2015. Bioconjugates for Targeted Delivery of Therapeutic Oligonucleotides |pdf=|usr=}}{{25689735}} gab.com Text Bioconjugates for Targeted Delivery of Therapeutic Oligonucleotides JO: Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=25689735 #FOAvip Bioconjugates have been used to deliver therapeutic oligonucleotides to their pharmacological targets in diseased cells. Molecular-scale conjugates can be prepared by directly linking targeting ligands with oligonucleotides and the resultant conjugates can selectively bind to cell surface receptors in target cells in diseased tissues. Besides targeted delivery, additional functionality can be incorporated in the conjugates by utilization of carrier molecules, and these larger conjugates are called carrier-associated conjugates. Both molecular and carrier-associated conjugates have achieved initial successes in clinical trials for treating liver diseases; therefore, currently the greater challenge is to deliver oligonucleotides to extrahepatic tissues such as tumors. This review will provide an update on the application of oligonucleotide conjugates for targeted delivery during the last decade. By identifying key elements for successful delivery, it is suggested that oligonucleotide conjugates with intermediate size, cell targeting ability, and endosomal release functionality are superior systems to advance oligonucleotides to achieve their full therapeutic potentials. Twit Text FOAVip Bioconjugates for Targeted Delivery of Therapeutic Oligonucleotides ????Adv Drug Deliv Rev http://www.kidney.de/pget.php?&tw=1&pmid=25689735 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25689735 #FOAvip English Wikipedia <ref>{{Cite pmid|25689735}}</ref> Bioconjugates for Targeted Delivery of Therapeutic Oligonucleotides #MMPMID25689735 Ming X; Laing B Adv Drug Deliv Rev 2015[Jun]; 87 (ä): 81-9 PMID25689735show ga Bioconjugates have been used to deliver therapeutic oligonucleotides to their pharmacological targets in diseased cells. Molecular-scale conjugates can be prepared by directly linking targeting ligands with oligonucleotides and the resultant conjugates can selectively bind to cell surface receptors in target cells in diseased tissues. Besides targeted delivery, additional functionality can be incorporated in the conjugates by utilization of carrier molecules, and these larger conjugates are called carrier-associated conjugates. Both molecular and carrier-associated conjugates have achieved initial successes in clinical trials for treating liver diseases; therefore, currently the greater challenge is to deliver oligonucleotides to extrahepatic tissues such as tumors. This review will provide an update on the application of oligonucleotide conjugates for targeted delivery during the last decade. By identifying key elements for successful delivery, it is suggested that oligonucleotide conjugates with intermediate size, cell targeting ability, and endosomal release functionality are superior systems to advance oligonucleotides to achieve their full therapeutic potentials. äBioconjugates for Targeted Delivery of Therapeutic Oligonucleotides (epmc).pdf DeepDyve Pubget Overpricing